Brief: SynAct Pharma Q2 Sales SEK 0
20/08/2024 06:30
Aug 20 (Reuters) - SynAct Pharma Q2 adjusted EPS SEK -0.47. * Q2 net income SEK -18.628 million * Q2 operating expenses SEK 19.167 million * Q2 cash flow from operating activities SEK -36.153 million
Recent news on SynAct Pharma AB
See all newsBrief: SynAct: Shareholding Board, Management Sign Lock-Up Agreements
Sweden's SynAct Pharma posts wider Q1 net loss as expenses rise
Brief: SynAct Pharma Q1 Sales SEK 0
Brief: SynAct Pharma Carries Out Directed Issue Of New Shares
Brief: Synact Pharma Appoints Ann Kristin Led As CFO Effective March 2026